Other languages Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
0.7001 ^USD	-2.36%		-0.67%	-2.76%

05-01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
04-29	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	05-01
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	12-21
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	12-21
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23/10/23
Galecto Announces Plans to Explore Strategic Alternatives	26/09/23
Galecto to Explore Strategic Options, to Reduce Workforce	26/09/23
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	26/09/23
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	26/09/23
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	15/08/23
Sector Update: Health Care Stocks Easing Tuesday Afternoon	15/08/23
Top Midday Decliners	15/08/23
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall	15/08/23
Galecto to discontinue development of lung disease treatment	15/08/23
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	15/08/23
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	31/07/23
Galecto Completes Patient Dosing in Mid-Stage Trial of Lung Disease Drug Candidate	23/05/23
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Galecto, Inc.

Equities

GLTO

US36322Q1076

Other languages

Filters